#USA #oncology #Florida Cancer Specialists #Fort Myers #Physician Leadership

Florida Cancer Specialists' Commitment to Physician Leadership

Florida Cancer Specialists & Research Institute, LLC (FCS) has recently made significant appointments in its physician leadership roles, emphasizing its dedication to enhancing cancer treatment through collaborative expertise. The new configurations within the leadership team reflect the growing diversity and specialization across the organization’s cancer programs, ensuring patients receive comprehensive and innovative solutions in their treatment plans.

Leadership Developments

One of the key appointments is that of Dr. Sachin Kamath, who expands his role as the medical director of radiation oncology to include radiology administration. Since joining FCS in 2015, Dr. Kamath has been instrumental in introducing cutting-edge evidence-based treatments such as stereotactic radiosurgery and radiotherapy, contributing significantly to clinical research and acquiring numerous honors in the process. His medical education was completed at the University of Florida at Gainesville.

Another prominent addition is Dr. Anton Serafini, named medical director of clinical radiology. Dr. Serafini has a commendable background, holding several leadership roles in private practices, academic institutions, and hospital settings since he earned his medical degree with research honors from the University of Miami School of Medicine. His extensive training included a five-year combined residency in diagnostic radiology and nuclear medicine at Jackson Memorial Hospital in Miami. Dr. Serafini joined FCS in 2024, bringing a wealth of experience and knowledge.

FCS's leadership structure now consists of six medical directors:
Dr. Wilfredo Blasini – Medical Director, Central Pathology
Dr. Sachin Kamath – Medical Director, Radiation Oncology and Radiology Administration
Dr. Bradley Monk – Medical Director, Late-Phase Clinical Research
Dr. Manish R. Patel – Medical Director, Drug Development
Dr. Anton Serafini – Medical Director, Clinical Radiology
Dr. Jessica Stine – Medical Director, Gynecologic Oncology

The organization believes that having physician leadership is crucial for advancing high-caliber cancer care. In line with this philosophy, several medical oncologists and hematologists have been confirmed into directorship roles for the term of 2025-2026. Notable appointments include:
Dr. Luis Carrascosa – Radiopharmaceutical Therapy
Dr. Matthew Fink – Physician Compensation and Finance
Dr. Gustavo Fonseca – Research and Clinical Trials
Dr. Alexander Glick – Pharmacy and Therapeutics
Dr. Maen Hussein – Value-Based Care
Dr. Scott Lunin – Physician Engagement
Dr. Richard McDonough – Advocacy and Policy
Dr. Ke Ning – Cell Therapy
Dr. Ameet Patel – Cell Therapy
Dr. Anjan Patel – Pharmacy and Therapeutics
Dr. Shachar Peles – Cell Therapy
Dr. Frank Rodriguez – Physician Engagement

In addition to medical directorships, the appointment of committee leadership has also taken place.

• - Dr. Lucio N. Gordan, FCS's president and managing physician, is the chair for Disciplinary and Ethics.
• - Dr. David Wenk, the assistant managing physician, takes on the role of co-chair for Compensation and Finance alongside Dr. Matthew Fink.
• - Dr. Jorge Ayub oversees Quality as chair.
• - Dr. Sachin Kamath is responsible for Compliance as chair.
• - Dr. Paresh Patel supports Quality as vice chair.

A Unified Approach to Patient Care

Ryan Ciarrocchi, the Chief Executive Officer of FCS, highlighted the importance of collaboration between physician leaders and executive management, stating, “This partnership ensures that every FCS patient benefits from the collective expertise of our entire care team. Our unified goal is to provide what is best for each individual we serve.”

About FCS

For over 40 years, Florida Cancer Specialists & Research Institute has focused on implementing innovations in patient care. With a robust clinical research program, FCS is recognized as a leader in private oncology practice within Florida and beyond. The practice provides patients with access to numerous clinical trials and offers a range of cutting-edge treatments. It is worth noting that many new cancer drugs in the U.S. were initially accessible to patients through participation in trials conducted at FCS before receiving FDA approval.

FCS prides itself on having a dedicated team of highly trained physicians committed to delivering tailored treatment plans that utilize the latest advancements in precision oncology to enhance patient outcomes.